Apolipoprotein E secretion by macrophages: Its potential physiological functions

Current Opinion in Lipidology

Volumn 7, Issue 5, 1996, Pages 303-307

  Mazzone, Theodore ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; GROWTH FACTOR;

ARTERY MUSCLE; ARTERY WALL; ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; HUMAN; LIPOPROTEIN SECRETION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MUSCLE GROWTH; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTE AGGREGATION;

EID: 0029849575     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199610000-00008     Document Type: Short Survey

References (46)

1. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer BH: Familial apolipoprotein E deficiency. J Clin Invest 1986, 78:1206-1219.
2. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
3. Scheer WD, Boudreau DA, Malcom GT, Middaugh JP: Apolipoprotein E and atherosclerosis in Alaska Natives. Atherosclerosis 1995, 114:197-202.
4. O'Brien KD, Deeb SS, Ferguson M, McDonald TO, Allen MD, Alpers CE, Chait A: Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase. Am J Pathol 1994, 144:538-548.
5. Rosenfeld ME, Butler S, Ord VA, Lipton BA, Dyer CA, Curtiss LK, Palinski W, Witztum JL: Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb 1993, 13:1382-1389.
6. Mazzone T, Basheeruddin K, Poulos C: Regulation of macrophage apolipoprotein E gene expression by cholesterol. J Lipid Res 1989, 30: 1055-1064.
7. Mazzone T, Gump H, Diller P, Getz GS: Macrophage free cholesterol content regulates apolipoprotein E synthesis. J Biol Chem 1987, 262:11657-11662.
8. Mazzone T, Pustelnikas L, Reardon CA: Post-translational regulation of macrophage apolipoprotein E production. J Biol Chem 1992, 267:1081-1087.
9. Lin RC, Dai J, Lumeng L, Zhang M: Serum low density lipoprotein of alcoholic patients is chemically modified in vivo and induces apolipoprotein E synthesis by macrophages. J Clin Invest 1995, 95:1979-1986.
10. Zhang M, Lin RC: Oxidative-modified and acetylated low-density lipoproteins differ in their effects on cholesterol synthesis and stimulate synthesis of apolipoprotein E in rat peritoneal macrophages by different mechanisms. Metabolism 1994, 43:1523-1530.
11. Hongwei D, Li Z, Mazzone T: Tumor necrosis factor-a modulates monocyte/macrophage apoprotein E gene expression. J Clin Invest 1995, 96:915-922. Demonstration of a phenotype-specific effect of tumor necrosis factor alpha on monocyte or macrophage apoE expression. Whereas tumor necrosis factor alpha could inhibit apoE expression in fully differentiated macrophages, it stimulated apoE expression in the monocytic or early macrophage phenotype. Such stimulation largely occurred at a level of apoE gene transcription.
12. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
13. Zhang SH, Reddick RL, Burkey B, Maeda N: Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 1994, 94:937-945.
14. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 133-140.
15. Reddick RL, Zhang SH, Maeda N: Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. Arterioscler Thromb 1994, 14:141-147.
16. van Ree JH, Gijbels MJJ, van den Broek WJ, Hofker MH, Havekes LM: Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis 1995, 112:237-243.
17. Linton MF, Atkinson JB, Fazio S: Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037. Bone marrow transplanted from wild type mice to apoE null mice was demonstrated to reduce circulating cholesterol levels and reduce the extent of atherosclerosis. These benefits were achieved even though circulating apoE levels were only 10-15% of normal.
18. Boisvert WA, Spangenberg J, Curtiss LK: Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995, 96:1118-1124. Transplantation of bone marrow from normal mice to apoE null mice reduced circulating lipid levels and protected against atherosclerosis. The results of this study and the one above demonstrate that macrophage-derived apoE can play a significant role in organismal lipoprotein transport and vessel wall homeostasis.
19. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y, Yamada N: Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 1995, 95:469-476. A transgenic mouse was developed that expressed high levels of apoE in the arterial wall while expression was low in other tissues. These mice were created on a background of normal hepatic apoE expression so they showed no difference in lipoprotein profile compared with wild type mice on normal and atherogenic diets. Overexpression of apoE in the vessel wall conferred significant resistance to the development of atherosclerosis and appeared to enhance efflux of cholesterol out of the vessel wall.
20. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE: Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995, 96:2170-2179. This study utilized apoE null mice and examined the effect of macrophage-specific apoE expression on vessel wall disease. Atherosclerotic lesion development was significantly less in mice expressing macrophage-specific apoE compared with littermates controlled for cholesterol level. These results convincingly demonstrate that macrophage-derived apoE is anti-atherogenic even in the presence of high levels of circulating atherogenic lipoproteins.
21. Kruth HS, Skarlatos SI, Gaynor PM, Gamble W: Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J Biol Chem 1994, 269:24511-24518.
22. 3. J Lipid Res 1994, 35:1345-1353.
23. Ball RY, Stowers EC, Burton JH, Cary NRB, Skepper JN, Mitchinson MJ: Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995, 114:45-54.
24. 3, does not reduce cellular cholesterol content. This observation, along with previous observations that endogenous expression of apoE by J774 cells does enhance cholesterol efflux, suggests that endogenous production of apoE by macrophages is important for modulating macrophage cholesterol homeostasis.
25. Leblond L, Marcel YL: Uptake of high density lipoprotein cholesterol ester by HepG2 cells involves apolipoprotein E localized on the cell surface. J Biol Chem 1993, 268:1670-1676.
26. Prack MM, Rothblat GH, Erickson SK, Reyland ME, Williams DL: Apolipoprotein E expression in Y1 adrenal cells is associated with increased intracellular cholesterol content and reduced free cholesterol efflux. Biochemistry 1994, 33:5049-5055.
27. Hara H, Yokoyama S: Interaction of free apolipoproteins with macrophages. J Biol Chem 1991, 266:3080-3086.
28. Li Q, Czarnecka H, Yokoyama S: Involvement of a cellular surface factor(s) in lipid-free apolipoprotein-mediated cellular cholesterol efflux. Biochim Biophys Acta 1995, 1259:227-234.
29. Bielicki JK, Johnson WJ, Weinberg RB, Glick JM, Rothblat GH: Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res 1992, 33:1699-1709.
30. Huang Y, Eckardstein A, Wu S, Assmann G: Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest 1995, 96:2693-2701.
31. Huang Y, Eckardstein A, Wu S, Maeda N, Assmann G: A plasma lipoprotein containing only apolipoprotein E and with y mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A 1994, 91:1834-1838.
32. Li Q, Yokoyama S: Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells. J Biol Chem 1995, 270:26216-26223.
33. Nathan CF: Secretory products of macrophages. J Clin Invest 1987, 79:319-326.
34. Desai K, Bruckdorfer R, Hutton RA, Owen JS: Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 1989, 30:831-840.
35. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6:131-138.
36. Kelly ME, Clay MA, Mistry MJ, Hsieh-LI H, Harmony JA: Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994, 159:124-139.
37. Clay MA, Anantharamaiah GM, Mistry MJ, Balasubramaniam A, Harmony JA: Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry 1995, 34:11142-11151.
38. Lucas M, Mazzone T: Cell-surface proteoglycans modulate net synthesis and secretion of macrophage apoE. J Biol Chem 1996, 271: 13454-13460. This study showed that apoE produced by macrophages is sequestered in a pericellular proteoglycan matrix. ApoE trapped in this matrix is subject to rapid reuptake and degradation by the macrophage. Alteration of composition of the pericellular matrix which accompanies macrophage differentiation or activation will therefore post-translationally modulate net secretion of apoE.
39. Saxena U, Ferguson E, Bisgaier CL: Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J Biol Chem 1993, 268:14812-14819.
40. Campbell JH, Kalevitch SG, Rennick RE, Campbell GR: Extracellular matrix-smooth muscle phenotype modulation by macrophages. Ann N Y Acad Sci 1990, 598:159-166.
41. Reyland ME, Williams DL: Suppression of cAMP-mediated signal transduction in mouse adrenocortical cells which express apolipoprotein E J Biol Chem 1991, 266:21099-21104.
42. Reyland ME, Gwynne JT, Forgez P, Prack MM, Williams DL: Expression of the human apolipoprotein E gene suppresses steroidogenesis in mouse Y1 adrenal cells. Proc Natl Acad Sci U S A 1991, 88:2375-2379.
43. Dyer CA, Curtiss LK: Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis. J Biol Chem 1988, 263:10965-10973.
44. Nicosia M, Moger WH, Dyer CA, Prack MM, Williams DL: Apolipoprotein-E messenger RNA in rat ovary is expressed in theca and interstitial cells and presumptive macrophage, but not in granulosa cells. Mol Endocrinol 1992, 6:978-988.
45. Browning PJ, Roberts DD, Zabrenetzky V, Bryant J, Kaplan M, Washington RH, Panet A, Gallo RC, Vogel T: Apolipoprotein E (apoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med 1994, 180:1949-1954.
46. Vogel T, Guo N, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD: Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994, 54:299-308.